Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

(S)-Methadone

Home Drugs(S)-Methadone

(S)-Methadone

Unknown Manufacturer

Generate AI report

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Patents

One entry per invention. Patent families filed in the US, EP, WO and CN offices.

NOVEL METHODS FOR SYNTHETIZING ENANTIOPURE (S)-METHADONE, (R)-METHADONE, RACEMIC (R,S)-METHADONE AND RELATED ANALOGUE SUBSTANCES
EP 4319733 C0Applicant: MANFREDI PAOLO LPriority: 2021
CN
EP
US
WO
4 publications
Method of treating addictions to opioids
US 10471052 B2Applicant: MYMD PHARMACEUTICALS INCPriority: 2018
US
2 publications
Enzyme-cleavable methadone prodrugs and methods of use thereof
US 12384744 B2Applicant: ENSYSCE BIOSCIENCES INCPriority: 2022
US
2 publications
Methadone chiral isolate as an improved pharmaceutical
US 2010010096 A1Applicant: SOMBERG JOHN CHARINPriority: 2009
US
SYNTHESIS AND PHARMACOLOGICAL EVALUATION OF ENANTIOMERICALLY PURE (R)- AND (S)-METHADONE METABOLITES AS N-METHYL-D-ASPARTATE RECEPTOR ANTAGONISTS
WO 2026044160 A1Applicant: UNIV OF PADOVAPriority: 2024
WO